Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07133230

Neurocognitive Correlates of the Influence of Number Word Syntax on Magnitude Processing

Linguistic irregularities in number naming systems, such as the inversion of number words, affect the processing of Arabic numerals. Recently, it has been claimed that there is even a syntactic representation of number words. participant investigate the neurofunctional correlates of the syntactic processing of number words by examining different levels of place-value processing in a study with two complementary successive phases (Group 1 and Group 2) in healthy adults. In the first phase with Group 1, participant evaluate the unit-decade compatibility effect (UDCE) in two-digit magnitude comparisons. In the second phase with Group 2, participant investigate the carry-over effect in two-digit addition problems.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

GHU Ste Anne

Paris, 75014, France

Location contact

Elise KLEIN

CONTACT

About this study

Selection visit

  • Call for participants for pre-selection
  • Sending of information forms by mail
  • Making an appointment for the inclusion visit at GHU Paris
  • Information on the modalities, constraints and foreseeable risks of the study
  • Collection of informed consent
  • Verification of inclusion/non-inclusion criteria
  • Clinical examination:
  • Verification of medical history and drug treatments
  • Psychiatric pathology
  • Consumption of toxic substances (nicotine, alcohol, cannabis, etc.)
  • Manual lateralization will be assessed by the score on the Edinburgh questionnaire (Oldfield, 1971)
  • Collection of main medical history and concomitant treatments
  • Explanation of study procedures
  • MRI examination

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject aged 18 to 45 years;
  • Female or male;
  • Right-handed preference;
  • Subject, or legal representative, who has given consent to participate;
  • Native language: French
  • Subject affiliated with a social security system;
  • Having signed their consent to participate (and their legal representative if applicable),
  • Subjects have read the information letter and given their free and informed consent;
  • Normal medical, neurological, and neuroradiological examinations
  • For women of childbearing age, be on effective contraception

Exclusion criteria

  • Not corresponding to the targeted age range;
  • Subject with contraindications to an MRI examination (pacemaker or neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign bodies in the eyes or brain near neural structures, metal prostheses, patient agitation: non-cooperative or agitated patients, minors, claustrophobic subjects, pregnant women, ventriculoperitoneal neurosurgical shunt valves, dental braces);
  • Subject with chronic alcohol or drug use;
  • Abuse or dependence on substances (except nicotine) or toxic substances for more than 5 years or having led to comas (overdoses);
  • Subject with sudden-onset cognitive disorders that could indicate a stroke; a history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;
  • Subject with chronic neurological, psychiatric, endocrine, hepatic, or infectious conditions;
  • Subject with a history of major illness (diabetes, chronic lung disease, severe cardiac, metabolic, hematological, endocrine, or immunological disorder, cancer);
  • Subject on medication: taking medications likely to interfere with brain imaging measurements (psychotropics, anxiolytic hypnotics, neuroleptics, anti-Parkinsonians, benzodiazepines, steroidal anti-inflammatories, antiepileptics, central analgesics, and muscle relaxants);
  • Color blindness;
  • Inability to comply with the study for geographical or psychiatric reasons;
  • Tattoo incompatible with MRI;
  • Cerebral palsy;
  • Fine motor skills disorder;
  • Pregnant women at the time of inclusion;
  • Adult subjects under legal protection or unable to give consent (article L.1121-8 of the French Public Health Code) (under guardianship or curatorship);
  • Children and parents under legal protection measures

Treatment and study plan

Primary outcomes

  1. Neurofunctional variables (fMRI)

    Time frame: Day 1

    the comparison of pairs of incompatible numbers compared to pairs of compatible numbers during the comparison of numbers.

  2. Structural variables (structural MRI)

    Time frame: Day 1

    the comparison of problems of addition with and without restraint during mental arithmetic.

  3. Behavioral variables,

    Time frame: Day 1

    we compare performance to the post-imaging reading test

  4. structural variables

    Time frame: Day 1

    recording of morphological and brain morphometric characteristics.

Secondary outcomes

  1. Handedness score

    Time frame: Day 1

    Measuring the lateralization of the hand will allow to recognize, based on the proposed activities, the dominant hand.

  2. Demographics questionnaire

    Time frame: Day 1

    this questionnaire which will allow the collection of all the precise information about the participant

Study contacts

Contact information is provided by the study sponsor or research team.

Elise Klein

CONTACT

[email protected]

+49 175 2042210‬

Sponsors and collaborators

Lead sponsor

Centre Hospitalier St Anne

Other

Registry information

Acronym: NUMWORD

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 20, 2025
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.